湖 北 华 强 科 技 股 份 有 限 公 司 内 部 控 制 审 计 报 告 天 职 业 字 [2024]22695 号 目 录 内 部控制审计报告一 -1 " 报告 内部控制审计报告 天职业字[2024]22695 号 湖北华强科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了湖 北华强科技股份有限公司(以下简称"华强科技"或"公司")2023年12月31日的财务报告 内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指引》 的规定,建立健全和有效实施内部控制,并评价其有效性是华强科技董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制审计报告 天职业字[2024]22695 号 [此页无正文] 中国注册会计师 (项目合伙人): 010150 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制变 ...

关于湖北华强科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1 1、 专项审计报告 2、 附表 委托单位：湖北华强科技股份有限公司 审计单位：天职国际会计师事务所（特殊普通合伙） 联系电话：0717-6347288 2 | | | | | 2023 年度非经营性资金占用及其他关联资金往来情况汇 | | | | | 单位:人民币万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 金占用方名粉 | 用方与上市公 司的关联关 | 市公司核 的会计科目 | 023 年期初 用资金余额 | 23 年度占用累 金额(不含利用 | 023 年度占用 的利息(如有 | 023 年度偿 景计发生金 | 023 年期 用资金余 | 占用形成原 | 与用性 | | 994 BB 大股东及其附属企 | 无 无 | | | | | | | | | 经营性占 经营性占用 | | 总计 | | | | | | | | | | | | 它关联资金往 | 资金往来方名称 | 来方与上市公 的关联关 ...

证券代码：688151 证券简称：华强科技 公告编号：2024-018 单位：元 | | | | 占 2023 年经审计归属 | | --- | --- | --- | --- | | 类别 | 资产名称 | 本期发生额 | 母公司股东净利润的 | | | | | 比例 | | 信用减值损失（损 | 应收账款信用减值损失 | -14,359,647.85 | -181.19% | | 失以"-"填列） | 其他应收款信用减值损失 | -5,749.05 | -0.07% | 1 | 类别 | 资产名称 | 本期发生额 | 占 2023 年经审计归属 | | --- | --- | --- | --- | | | | | 母公司股东净利润的 | | | | | 比例 | | 小计 | | -14,365,396.90 | -181.26% | | 资产减值损失（损 | 存货减值损失 | -11,664,198.76 | -147.18% | | 失以"-"填列） | 小计 | -11,664,198.76 | -147.18% | | 合计（损失以"-"填列） | | -26,029,595.66 | -328 ...

华泰联合证券有限责任公司 关于湖北华强科技股份有限公司 预计2024年度日常关联交易的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为湖北华强科技股份有限公司（以下简称"华强科技"或"公司"）首次公开 发行股票并在科创板上市持续督导阶段的保荐机构，根据《证券发行上市保荐 业务管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创 板上市公司自律监管指引第 1 号——规范运作》等相关法律法规和规范性文件 的规定，对公司预计 2024 年度日常关联交易的事项进行了认真、审慎的核查， 具体情况如下： 一、日常关联交易的基本情况 （一）日常关联交易履行的审议程序 2024 年 4 月 25 日，公司召开第二届董事会第六次会议，审议通过了《预计 2024 年度日常关联交易的议案》，关联董事唐伦科先生、张亚昌先生、邹晓丽女 士、徐斌先生回避表决，其余非关联董事对该议案一致同意。表决程序符合《公 司法》《证券法》等法律法规以及《公司章程》的有关规定。表决结果：5 票同 意，0 票反对，0 票弃权。 2024 年 4 月 25 日，公司召开第二届监事会第三次会议，审议通过了《预计 ...

关于湖北华强科技股份有限公司 会计政策、会计估计变更 和 会 计 差 错 更 正 事 项 的 专 项 说 明 天职业字[2024]22723 号 您可使用手机"扫一扫"或进入"注册用于证明这审计报告是否由具有执业许可的会计师事务所出具 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（htm://42c.mot.gov.cn）"进行企 关于湖北华强科技股份有限公司 会计政策、会计估计变更和会计差错更正事项的专项说明 天职业字[2024]22723 号 湖北华强科技股份有限公司全体股东: 我们接受委托,审计了湖北华强科技股份有限公司(以下简称"华强科技"或"公司")2023 年度的财务报表,并出具了标准无保留意见的审计报告(报告编号:天职业字[2024]17881 号)。 根据上海证券交易所《关于做好 2023年年度报告工作的通知》要求,现将华强科技有关会计 政策、会计估计变更和会计差错更正事项说明如下: 一、会计政策变更 公司自 2023年1月1日采用《企业会计准则解释第16 号》(财会(2022)31 号)相关规定, 根据累积影响数调整财务报表相关项目金额。上述会计政策变更对公司财务报表无影响。 二 ...

华泰联合证券有限责任公司 关于湖北华强科技股份有限公司 2023 年度募集资金存放与使用情况的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"） 作为湖北华强科技股份有限公司（以下简称"华强科技"或"公司"）首次公开 发行股票并在科创板上市持续督导阶段的保荐机构。根据《证券发行上市保荐业 务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监 管要求》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》）等法律法规的规定，对华强科技 2023 年度募集资金存放与使用情况进行了审慎核查，具体情况如下： 一、募集资金的基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意湖北华强科技股份有限公司首次公 开发行股票注册的批复》（证监许可〔2021〕3368 号）同意注册，公司向社会公 开发行人民币普通股 8,620.62 万股，每股面值人民币 1 元，每股发行价为人民 币 35.09 元，募集资金总额为人民币 302,497.56 万元，扣除发行费用（不含增值 税）人民币 21,282.47 ...

Financial Performance - Total operating revenue for 2023 was corrected to ¥57,275.31 million, a decrease of 2.21% from the previous year's ¥58,567.94 million[1]. - Operating profit was revised to ¥477.45 million, reflecting a significant decline of 92.52% compared to ¥6,387.20 million in the prior year[1]. - Total profit was adjusted to ¥414.26 million, down 93.41% from ¥6,287.89 million year-over-year[1]. - Net profit attributable to shareholders was corrected to ¥792.51 million, an 88.36% decrease from ¥6,807.26 million in the previous year[1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was revised to -¥7,602.74 million, a drastic change from -¥1,292.02 million in the prior year, indicating a decline of 488.44%[1]. - Basic earnings per share remained at ¥0.02, down 90% from ¥0.20 in the previous year[1]. - Total assets at the end of the reporting period were corrected to ¥505,164.53 million, a decrease of 2.13% from ¥516,166.15 million at the beginning of the period[1]. Regulatory and Compliance Issues - The company received regulatory warnings from the Hubei Securities Regulatory Bureau and the Shanghai Stock Exchange regarding the need for corrections in previous financial reports[4]. - The company expressed sincere apologies to investors for the impact of the earnings report correction[7]. - The board will enhance supervision and training on financial accounting standards to improve the quality of financial information[8].

证券代码：688151 证券简称：华强科技 公告编号：2024-021 湖北华强科技股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2023 年年度股东大会 召开日期时间：2024 年 5 月 17 日 14 点 00 分 召开地点：中国（湖北）自贸区宜昌片区生物产业园东临路 499 号会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 17 日 至 2024 年 5 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过互联 1 股东大会召开日期：2024年5月17日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） ...

Financial Performance - The company reported a total distributable profit of RMB 291,352,150.30 as of December 31, 2021[6]. - A cash dividend of RMB 3.35 per 10 shares (including tax) is proposed, amounting to a total of RMB 115,407,500.00 (including tax) based on a total share capital of 344,500,000 shares[6]. - The cash dividend represents 36.04% of the net profit attributable to shareholders of the parent company for the year[6]. - In 2021, the company's operating revenue increased by 52.64% year-on-year, reaching ¥1,274,716,156.37, primarily due to the sales growth of vaccine-related products and collective protection products[22]. - The net profit attributable to shareholders of the listed company surged by 81.15% to ¥319,190,437.72, driven by increased production and sales of pharmaceutical packaging and collective protection products[22]. - The net cash flow from operating activities rose significantly by 250.88% to ¥472,426,883.36, attributed to favorable sales collection from military and major clients[24]. - The company's total assets at the end of 2021 amounted to ¥5,291,957,302.50, reflecting a 128.98% increase compared to the previous year[22]. - The net assets attributable to shareholders of the listed company increased by 265.49% to ¥4,232,666,496.85[22]. - Basic earnings per share for 2021 were ¥1.24, representing a 69.86% increase from the previous year[23]. - The gross profit margin for the main business was 42.70%, an increase of 11.34 percentage points year-on-year[70]. - The gross profit margin for special protective products was 15.77%, a decrease of 12.52 percentage points year-on-year[70]. Research and Development - The research and development expenditure accounted for 4.62% of operating revenue, slightly down from 4.74% in 2020[23]. - The company achieved a significant increase in R&D expenses, totaling approximately ¥58.92 million, representing a year-on-year growth of 48.72%[54]. - R&D expenses accounted for 4.62% of total revenue, a slight decrease of 0.12 percentage points compared to the previous year[53]. - The company holds a total of 212 intellectual property rights, including 89 invention patents, with 18 new applications filed during the reporting period[51]. - The company has developed 14 core technologies in special protection and medical packaging, enhancing its competitive edge in the market[50]. - The company is committed to expanding its research directions and scale to maintain its technological advantage in the industry[54]. - The company is focusing on building a high-quality manufacturing innovation network to meet national emergency response needs and improve capabilities[116]. Market and Product Development - The company plans to continue expanding its market presence and enhancing product offerings in the pharmaceutical packaging and collective protection sectors[24]. - The company is positioned as a professional military enterprise in the field of special protection, with a strong emphasis on research and development of protective equipment and medical packaging[35]. - The company specializes in individual protective equipment, primarily producing breathable protective suits and masks for military use, having developed three generations of these suits[36]. - The collective protective equipment includes various components such as pre-filters and ventilation devices, directly supplied to military units[36]. - The medical packaging and medical device segment includes products like pharmaceutical butyl rubber stoppers and medical masks, with the company becoming a core supplier for COVID-19 vaccine stoppers[36]. - The company has established long-term cooperative relationships with major pharmaceutical enterprises, including China National Pharmaceutical Group and Guangzhou Pharmaceutical Group[66]. - The company is committed to improving product quality by deepening quality system management and ensuring effective operation of the quality system[119]. Operational Efficiency - The company achieved intelligent production processes for pharmaceutical butyl rubber stoppers, establishing long-term partnerships with numerous pharmaceutical enterprises[36]. - The company has completed 70% of the military's current orders for breathable gas masks and 100% for specialized gas masks, solidifying its core position in the defense industry[47]. - The company has established a structured procurement process, categorizing suppliers into five types based on importance, ensuring quality and timely delivery[39]. - Military products are produced under strict military standards with real-time supervision, while civilian products follow a market-driven production model[40]. - The company has a significant reliance on foreign suppliers for raw materials, primarily from the US, Europe, Russia, and Japan, which poses risks to production and cost control[69]. - The company has a high concentration of accounts receivable, with a balance of 605.03 million RMB, accounting for 13.45% of current assets[71]. Corporate Governance and Compliance - The company has established a governance structure with a board of 9 directors, including 3 independent directors, and has formed specialized committees to ensure effective decision-making[124]. - In 2021, the company held 3 shareholder meetings and 9 board meetings, reviewing a total of 66 proposals, ensuring compliance with legal and regulatory requirements[125]. - The company emphasizes the independence of its operations, maintaining a clear separation from its controlling shareholders in business, personnel, assets, and finances[125]. - The company has established a comprehensive information disclosure management system, ensuring transparency and equal access to information for all shareholders[191]. - The company has implemented a robust ESG strategy, integrating it into core business operations to enhance long-term sustainability[168]. - The company has not faced any administrative penalties related to environmental issues in 2021[170]. Social Responsibility - The company donated a total of 5 million yuan for poverty alleviation projects, including 500,000 yuan for targeted assistance in Yanshan, Yunnan[177]. - The company has maintained a strong focus on employee rights and welfare, continuously improving management systems related to employment and benefits[168]. - The company donated a total of 700,000 yuan in 2021 to support poverty alleviation and rural revitalization efforts, with 183,600 yuan specifically for consumption assistance[180]. Future Outlook - The company plans to expand its market presence by entering three new regions in 2022, aiming for a 20% increase in market share[130]. - The company is exploring acquisition opportunities to enhance its product portfolio, with a budget of $200 million allocated for potential mergers[136]. - The company provided guidance for 2022, expecting revenue growth to be between 10% and 12%, projecting total revenue to reach approximately 1.32 billion[140]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million earmarked for potential acquisitions in 2022[140].

重要内容提示： 每股分配比例：每 10 股派发现金红利 0.083 元（含税）。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。 证券代码：688151 证券简称：华强科技 公告编号：2024-015 湖北华强科技股份有限公司 关于 2023 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于 2024 年 4 月 25 日召开第二届董事会第六次会议，以 9 票同意，0 票 反对，0 票弃权的表决结果审议通过《2023 年度利润分配方案》，并同意将该议 案提交公司 2023 年年度股东大会审议。 （二）监事会意见 在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配 总额不变，相应调整每股分配比例，并将另行公告具体调整情况。 一、利润分配方案内容 经天职国际会计师事务所（特殊普通合伙）审计，截至 2023 年 12 月 31 日， 湖北华强科技股份有限公司（以下简称"公司"）期末合并报表可供分配利润为 人民币235,276,213.60元， ...